COVID-19 Vaccines 2025-26 (United States)
full update September 2025
The first chart below provides dosing and storage information for COVID-19 vaccines approved in the US. Links to the prescribing information and the patient package insert are provided in footnote a. A second chart provides information and resources to help you address frequently asked questions about COVID-19 vaccination.
--Information in this chart is from the US product information (prescribing information or fact sheet) cited in footnote a, unless otherwise cited.--
Vaccine |
Dosing |
Storage/Stability |
Comirnaty COVID-19 vaccine, mRNA 2025 to 2026 formula (Omicron LP.8.1) for patients ≥65 years of age and Pfizer-BioNTech Syringe with gray label border. |
For patients ≥12 years of age:
|
|
Comirnaty COVID-19 vaccine, mRNA. 2025 to 2026 formula (Omicron LP.8.1) for patients 5 years through 11 years of age with certain risk factorsc Pfizer-BioNTech Vial with blue cap and label border. |
For patients 5 years through 11 years of age.
|
|
Spikevax COVID-19 vaccine, mRNA. 2025 to 2026 formula (Omicron LP.8.1) for patients ≥65 years of age and Moderna Syringe with blue box on label19 |
For patients ≥12 years of age.
|
|
Spikevax COVID-19 vaccine, mRNA. 2025 to 2026 formula (Omicron LP.8.1) for patients 6 months to 11 years of age with certain risk factorsc Moderna Syringe with red box on label19 |
|
|
mNexspike COVID-19 vaccine, mRNA. 2025 to 2026 formula (Omicron LP.8.1) for patients ≥65 years of age, and Moderna Syringe with green box on label20 |
For patients ≥12 years of age.
|
|
Nuvaxovid COVID-19 vaccine, adjuvanted. Novavax Syringe with yellow box on label23 |
|
|
Abbreviations: CDC = Centers for Disease Control; IM = intramuscular
- US prescribing information used in creation of this chart, and corresponding patient package inserts for recipient/caregiver:
- Comirnaty (August 2025): https://www.fda.gov/vaccines-blood-biologics/comirnaty.
- Spikevax (August 2025): https://www.fda.gov/vaccines-blood-biologics/spikevax.
- mNexspike (August 2025): https://www.fda.gov/vaccines-blood-biologics/mnexspike
- Nuvaxovid (August 2025): https://www.fda.gov/vaccines-blood-biologics/vaccines/nuvaxovid
- Immunocompromise = solid organ transplant patients or similar level of immunocompromise. For a full list of CDC-recommended conditions and vaccination recommendations, see CDC guidance at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.
- Risk factors: https://www.cdc.gov/covid/risk-factors/index.html. NOTE: Some organizations have recommendations for use that differ from the FDA-approved labeling (not all-inclusive):
- American Academy of Family Physicians: https://www.aafp.org/family-physician/patient-care/public-health-emergencies/recent-outbreaks/covid-19/covid-19-vaccine.html
- American Academy of Pediatrics: https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2025-073924/203222/Recommendations-for-COVID-19-Vaccines-in-Infants
- American College of Obstetricians and Gynecologists: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care
- CDC: https://www.cdc.gov/covid/hcp/vaccine-considerations/index.html
Frequently asked questions about COVID-19 vaccination
Question |
Pertinent information or Suggested Resources |
How do COVID-19 vaccines work? |
|
Do mRNA vaccines affect DNA? |
|
Can a COVID-19 vaccine cause a COVID-19 infection? |
|
Can a patient get a COVID-19 vaccine if they have a COVID infection? |
|
How effective are COVID-19 vaccines? |
|
What is the difference between Spikevax and mNexspike? |
|
Can COVID-19 vaccines be given with other vaccines? |
|
What are some common adverse effects of COVID-19 vaccines, and what can be done about them? |
|
Do COVID-19 vaccines cause heart problems? |
|
Do COVID-19 vaccines cause Bell’s palsy? |
|
Do COVID-19 vaccines cause Guillain-Barre syndrome? |
|
Will COVID-19 vaccination cause a positive COVID test? |
|
Can antibody testing be used to assess the need for COVID-19 vaccination? |
|
Do you need to stick with the same vaccine every year? |
|
Should a child receive one or two doses of Spikevax if they turn 2 years of age during the two-dose series? |
|
Do COVID-19 vaccines prevent “long COVID”? |
|
Can patients who are pregnant or breastfeeding get a COVID vaccine? |
|
References
- CDC. Long COVID basics. July 24, 2025. https://www.cdc.gov/covid/long-term-effects/index.html. (Accessed September 7, 2025).
- Trinh NT, Jödicke AM, Català M, et al. Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway. Lancet Respir Med. 2024 May;12(5):e33-e34.
- Al-Aly Z, Davis H, McCorkell L, et al. Long COVID science, research and policy. Nat Med. 2024 Aug;30(8):2148-2164.
- CDC. Getting your COVID-19 vaccine. June 11, 2025. https://www.cdc.gov/covid/vaccines/getting-your-covid-19-vaccine.html. (Accessed September 7, 2025).
- CDC. COVID-19 Vaccine Basics. September 3, 2024. https://www.cdc.gov/covid/vaccines/how-they-work.html. (Accessed September 7, 2025).
- Fairweather D, Beetler DJ, Di Florio DN, et al. COVID-19, Myocarditis and Pericarditis. Circ Res. 2023 May 12;132(10):1302-1319.
- Buoninfante A, Andeweg A, Genov G, Cavaleri M. Myocarditis associated with COVID-19 vaccination. NPJ Vaccines. 2024 Jun 28;9(1):122.
- CDC. Interim clinical considerations for use of COVID-19 vaccines in the United States. May 1, 2025. https://www.cdc.gov/covid/media/pdfs/2025/07/iCC_document_7.18.25.pdf. (Accessed September 7, 2025).
- Wallace M, Moulia D, Blain AE, et al. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):416-421.
- American College of Obstetricians and Gynecologists. Practice Advisory. COVID-19 vaccination considerations for obstetric-gynecologic care. Last updated August 2025. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care. (Accessed September 7, 2025).
- Jaffry M, Mostafa F, Mandava K, et al. No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study. Vaccine. 2022 Sep 22;40(40):5791-5797.
- CDC. Overview of testing for SARS-CoV-2. August 29, 2024. https://www.cdc.gov/covid/hcp/clinical-care/overview-testing-sars-cov-2.html. (Accessed September 7, 2025).
- Willison AG, Pawlitzki M, Lunn MP, et al. SARS-CoV-2 Vaccination and Neuroimmunological Disease: A Review. JAMA Neurol. 2024 Feb 1;81(2):179-186.
- Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1228-1232.
- CDC. Benefits of getting vaccinated. https://www.cdc.gov/covid/vaccines/benefits.html?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html. (Accessed September 7, 2025).
- Link-Gelles R, Chickery S, Webber A, et al. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27;74(6):73-82.
- CDC. Implementation guidance. May 1, 2025. https://www.cdc.gov/covid/hcp/vaccine-considerations/implementation.html. (Accessed September 7, 2025).
- FDA. FDA approves required updated warning in labeling of mRNA COVID-19 vaccines regarding myocarditis and pericarditis following vaccination. June 25, 2025. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-approves-required-updated-warning-labeling-mrna-covid-19-vaccines-regarding-myocarditis-and. (Accessed September 7, 2025).
- Spikevax. Product reimbursement information. August 2025. https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/41920bca-959f-4e5b-a77c-582a5e5b2dd1/41920bca-959f-4e5b-a77c-582a5e5b2dd1_viewable_rendition__v.pdf (Accessed September 13, 2025).
- mNexspike. 2025-2026 formula: product information guide. August 2025. https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/73cb8fd2-e19e-4e0b-8cd6-665a90b4b757/73cb8fd2-e19e-4e0b-8cd6-665a90b4b757_viewable_rendition__v.pdf (Accessed September 13, 2025).
- Chalkias S, Pragalos A, Akinsola A, et al. Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine. J Infect Dis. 2025 Apr 15;231(4):e754-e763.
- Prescribing information for mNexspike. Moderna US. Princeton, NJ 08540. August 2025.
- Prescribing information for Nuvaxovid. Novavax. Gaithersburg, MD 20878. August 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a20513c-d255-46d7-8e6b-294cec4b44f4. (Accessed September 15, 2025).
Cite this document as follows: Clinical Resource, COVID-19 Vaccines 2025-26 (United States). Pharmacist’s Letter/Pharmacy Technician’s Letter/Prescriber Insights. September 2025. [410968]